ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1508

Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging

Siba Raychaudhuri1, Yasser Abdelhafez2, Dario Mazza3, Smriti Raychaudhuri4 and Abhijit Chaudhari3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, 2University of California Davis, Sacramento, CA, 3UC Davis, School of Medicine, Sacramento, CA, 4VA Medical Center, Sacramento, CA

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Disease Activity, Imaging, Inflammation, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can’t be assessed; also can’t be differentiated from mechanical strain. The Total Body (TB)-PET/CT imaging with the 18F-FDG radiotracer captures glucose metabolism across the whole body. Thus identifies and provides a quantitative standardized measures as surrogates for the degree of systemic inflammation such as SUVmax. The objective of this study was to apply high-sensitivity TB 18F-FDG PET/CT imaging to characterize enthesitis and to determine the enthesitis burden in patients with PsA.

Methods: We prospectively recruited 20 untreated PsA patients (15 male,5 female; mean age of 56.8±16.3 years). All subjects underwent full rheumatological evaluation including Leeds enthesitis index (LEI) and a single-timepoint TB-PET/CT using 1/5th the standard radioisotope dose. 38 entheses per participant, so in 20 patients (38×20=760) were assessed. The evaluated entheses were derived from 6 different enthesitis outcome measures (LEI, San Francisco, MASES, MAJOR, SPARCC, and 4-Point enthesitis measures). Each enthesis was visually evaluated based on FDG uptake intensity using an ordinal score from 0 to 3 and quantitatively based on the maximum standardized uptake value ratio after correction to the background level (rSUVmax).

Results: Inflammation of enthesis per PET imaging was found in all subjects (n=20, 100%). Our findings suggest marked inflammation in entheses, and adjacent bone along with nail matrix inflammation in the DIP joints of PsA patients compared to OA (n=20) (Fig 1).

Here we are reporting extracted data on 15 patients. PET/CT was positive in 127 out of 543 evaluable enthesis (23.4%) in among 15 participants (average: 8.5 positive entheses per participant). The anatomical distribution of positive entheses is presented in Fig 2-A.

On clinical rheumatologic examination and PET/CT, respectively, 7 and 21 out of 82 evaluable LEI entheses were positive. PET/CT was positive in 5/7 tender entheses and detected inflammation in additional 16 LEI entheses (Fig 2-B).

SPARCC and San Francisco measures demonstrated the highest absolute number of positive entheses (66 and 59, respectively). However, components of LEI were, on average, the most metabolically active (Fig 3) with average summed rSUVmax of 14.1±9.8 compared to 8.0±5.1and 7.0±4.8 for SPARCC and San Francisco measures, respectively.

Conclusion:

1. Enthesitis likely to be a dominant pathology in PsA. TB-PET/CT scans were able to detect inflammation in significantly higher number of entheses ( >20%) when compared to rheumatologic examination of a specific clinical measure.

2. Our findings provides direct in-vivo evidence suggesting that the pathologic events in the DIP joints are largely entheseal based. We are generating data on larger patient population and expecting to substantiate this observation which will provide a broader understanding of the disease process of PsA.

3. In addition, this in-vivo imaging study provides the systemic burden of enthesitis (rSUVmax) in PsA. TB-PET/CT imaging will be able to quantify and monitor enthesial inflammatory burden in a patient and its therapeutic response.

Supporting image 1

Figure 1.
A. Demonstrates in PsA inflammation of the flexor and extensor tendon of the fingers and the association of the extensor tendon with its enthesitis of the DIP joint and adjacent nail matrix inflammation. Nail matrix is inflamed sparing the nail bed along with the adjacent inflammation of the extensor tendon at the site of insertion (enthesitis)
B. Compared to PsA there is no significant enthesitis at the DIP joint in rheumatoid arthritis or in osteoarthritis.

Supporting image 2

Figure 2.
A. Frequency of positive entheses on 18F-FDG total-body PET/CT according to their anatomical site.

Fig 2. B. Association of 18F-FDG total-body PET/CT findings with the rheumatological examination in a subset of the evaluated entheses (B).

Supporting image 3

Figure 3.

Total-Body PET/CT Evaluation of PsA: (A) Maximum-intensity projection (MIP) of a Total-Body PET scan demonstrating multiple active joints (shoulders, sternoclavicular joints, elbows, wrists, knees, ankles, left first MTP). Fused PET/CT images from different participants demonstrating enthesitis patterns throughout the body (B-G). The spine entheses are involved at the cervical (B, arrow at C7 and arrowhead at T3), and lumbar regions (C, arrow at L5 and arrowhead at L3/L4/L5 inter/supra-spinous ligaments). Other inflamed entheses include right supraspinatus (D), Achilles (E), and patellar tendons (F), and plantar fascia (G).


Disclosures: S. Raychaudhuri, AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Sun, UCB; Y. Abdelhafez, None; D. Mazza, None; S. Raychaudhuri, None; A. Chaudhari, None.

To cite this abstract in AMA style:

Raychaudhuri S, Abdelhafez Y, Mazza D, Raychaudhuri S, Chaudhari A. Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/enthesitis-a-dominant-pathology-in-psoriatic-arthritis-identification-and-quantification-of-enthesitis-burden-by-18f-fdg-total-body-pet-ct-imaging/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enthesitis-a-dominant-pathology-in-psoriatic-arthritis-identification-and-quantification-of-enthesitis-burden-by-18f-fdg-total-body-pet-ct-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology